The Hospital Bet That Reframes The Intuitive Surgical Stock Story
While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company’s core…
How Much Upside Is Left in JNJ Stock?
While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That…
Can Cost Cuts And 2030 Targets Really Save Pfizer Stock?
The company now leads with a cost-savings total and a growth rate that does not begin until the…
Can Eli Lilly Stock Keep Surging As Drug Prices Fall?
The past year’s gain was bought with volume and access, and management has already said net price goes…
Eli Lilly Found a New Gear. You Paid For It.
Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb…
Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant’s stock jump was about more than an earnings beat, offering proof of a growth story…
Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.
While investors fixate on slowing elective surgeries, a powerful, non-obvious growth engine is accelerating inside the company’s U.S.…
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
The Catch Hiding In Eli Lilly Stock’s Growth Story
Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
Johnson & Johnson, U.S. agree on drug discounts, new plants
Key Terms
tariffs
regulatory
Tariffs are taxes imposed by a government on goods…